Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6344-6351

  Smits, A ^a,b   De Cock, R F W ^c   Allegaert, K ^a,b   Vanhaesebrouck, S ^a,b   Danhof, M ^c   Knibbe, C A J ^c,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c LEIDEN UNIVERSITY   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; IBUPROFEN; ANTIINFECTIVE AGENT; CREATININE;

APGAR SCORE; ARTICLE; BIRTH WEIGHT; BLOOD SAMPLING; BODY WEIGHT; CLINICAL PRACTICE; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG MONITORING; ESCHERICHIA COLI; GESTATIONAL AGE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; NEWBORN; PERINATAL PERIOD; PREDICTION; PREMATURITY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAPHYLOCOCCUS EPIDERMIDIS; STEADY STATE; TERM BIRTH; THERAPEUTIC ERROR; VOLUME OF DISTRIBUTION; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; INFANT; MALE; MICROBIOLOGY; PATHOLOGY; PERSONALIZED MEDICINE; SEPSIS; STATISTICAL MODEL;

AMIKACIN; ANTI-BACTERIAL AGENTS; BIRTH WEIGHT; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MODELS, STATISTICAL; MONTE CARLO METHOD; PRECISION MEDICINE; PROSPECTIVE STUDIES; SEPSIS;

EID: 84942858669     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01157-15     Document Type: Article

References (23)

1. Knibbe CA, Danhof M. 2011. Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm 415:9-14. http://dx.doi.org/10.1016/j.ijpharm.2011.02.056.
2. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. 2011. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 67(Suppl 1):5-16. http://dx.doi.org/10.1007/s00228-009-0782-9.
3. Ince I, de Wildt SN, Tibboel D, Danhof M, Knibbe CA. 2009. Tailormade drug treatment for children: creation of an infrastructure for datasharing and population PK-PD modeling. Drug Discov Today 14:316-320. http://dx.doi.org/10.1016/j.drudis.2008.11.004.
4. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, Knibbe CA. 2012. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet 51:105-117. http://dx.doi.org/10.2165/11595640-000000000-00000.
5. Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM. 2009. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 65:705-713. http://dx.doi.org/10.1007/s00228-009-0637-4.
6. Allegaert K, Anderson BJ, Cossey V, Holford NH. 2006. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 61:39-48. http://dx.doi.org/10.1111/j.1365-2125.2005.02530.x.
7. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481-504. http://dx.doi.org/10.1023/A:1012299115260.
8. Anderson BJ, Holford NH. 2011. Tips and traps analyzing pediatric PK data. Paediatr Anaesth 21:222-237. http://dx.doi.org/10.1111/j.1460-9592.2011.03536.x.
9. Touw DJ, Westerman EM, Sprij AJ. 2009. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet 48:71-88. http://dx.doi.org/10.2165/00003088-200948020-00001.
10. Brendel K, Comets E, Laffont C, Laveille C, Mentre F. 2006. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:2036-2049. http://dx.doi.org/10.1007/s11095-006-9067-5.
11. Comets E, Brendel K, Mentre F. 2008. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R. Comput Methods Programs Biomed 90:154-166. http://dx.doi.org/10.1016/j.cmpb.2007.12.002.
12. De Hoog M, van den Anker J. 2010. Aminoglycosides and glycopeptides, p 412-435. In: Neonatal and pediatric pharmacology: therapeutic principles in practice, 4th ed. Lippincott, Williams and Wilkins, Philadelphia, PA.
13. Gouyon JB, Cransac A, Sgro C. 2012. Medication errors in neonatal medicine: from prescription to administration. Arch Pediatr 19:976-983. (In French.) http://dx.doi.org/10.1016/j.arcped.2012.06.006.
14. Downes KJ, Hahn A, Wiles J, Courter JD, Vinks AA. 2014. Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. Int J Antimicrob Agents 43:223-230. http://dx.doi.org/10.1016/j.ijantimicag.2013.11.006.
15. Pacifici GM. 2009. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol 65:419-427. http://dx.doi.org/10.1007/s00228-008-0599-y.
16. Cordero L, Kuehn L, Kumar RR, Mekhjian HS. 2004. Impact of computerized physician order entry on clinical practice in a newborn intensive care unit. J Perinatol 24:88-93. http://dx.doi.org/10.1038/sj.jp. 7211000.
17. National Patient Safety Agency. 2010. Neonatal services urged to follow new gentamicin safety guidance. National Patient Safety Agency, London.
18. Lingvall M, Reith D, Broadbent R. 2005. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol 59:54-61. http://dx.doi.org/10.1111/j.1365-2125.2005.02260.x.
19. Zhao W, Biran V, Jacqz-Aigrain E. 2013. Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates. Clin Pharmacokinet 52:1127-1134. http://dx.doi.org/10.1007/s40262-013-0101-6.
20. De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, Danhof M, Knibbe CA. 2014. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res 31:754-767. http://dx.doi.org/10.1007/s11095-013-1197-y.
21. Valitalo PA, van den Anker JN, Allegaert K, De Cock RF, de Hoog M, Simons SH, Mouton JW, Knibbe CA. 2015. Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. J Antimicrob Chemother 70:2074-2077. http://dx.doi.org/10.1093/jac/dkv052.
22. Knibbe CA, Krekels EH, Danhof M. 2011. Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol 7:1-8. http://dx.doi.org/10.1517/17425255.2011.539201.
23. Langhendries JP, Battisti O, Bertrand JM, François A, Kalenga M, Darimont J, Scalais E, Wallemacq P. 1998. Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit. Biol Neonate 74:351-362.